Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    16609087 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin;   Procedure: Definitive Surgery;   Radiation: Radiotherapy
2 Unknown  Combination Chemotherapy in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel

Indicates status has not been verified in more than two years